Back to news overview

Confo Therapeutics receives grant from VLAIO

The €1 million grant will be used to support the development of new methods for screening libraries of small molecules for the discovery of new therapeutic candidates targeting G-protein coupled receptors (GPCRs), using the company’s proprietary conformation-sensitive single domain antibodies or Confobodies.

Read the article here.